Inclusion of a compound does not constitute endorsement. Information sourced from published research and regulatory filings.
LL-37
Longevity & Immune · Research peptide (multiple suppliers)
Sole human cathelicidin antimicrobial peptide investigated for broad-spectrum antimicrobial activity, immune modulation, and wound healing. Not FDA-approved as a drug.
About
Clinical Dosing
Not FDA-approved as a drug. Cited concerns include cytotoxicity at high concentrations, immunogenicity, and possible protumorigenic effects in certain contexts. Topical formulations appear better tolerated than systemic use in available data.
Dosing based on small human studies or early-phase trials. Not established by Phase 3 evidence. Topical formulations have stronger clinical evidence (wound healing) than systemic injection.
Regulatory Status
Status based on publicly available FDA communications. Verify at FDA.gov for authoritative guidance.
View full regulatory timeline →Titration Protocols
Research Reference Range
Source: Vandamme et al., Cellular Immunology, 2012 (review)
| Dose | Duration | Draw (5 mg vial in 2mL) | Notes |
|---|---|---|---|
| 100 mcg | Maintenance | 0.04 mL (4 units) | Representative low-end community starting dose. Topical use is better characterized than systemic use. |
Available Vial Sizes
5 mg
5 mg vial
10 mg
10 mg vial
Citations
- [1]A Comprehensive Summary of LL-37, the Factotum Human Cathelicidin Peptide. Cellular Immunology, 280(1), 22-35. Link(Reviewed: 2026-04-16)